Anti-CD3 & DLL3 Reference Anti

The detected molecular weight of Anti-CD3 & DLL3 Reference Antibody (Tarlatamab) is 91.84 kDa. _x005f_x000D_ The antibody sequence matches the sequence in patent (WO2017021349).The Mass data suggested a smaller molecular weight of Tarlatamab (91.84 kDa) than the theoretical value (105.2 kDa, from the above patent). Functional assays domenstrated Tarlatamab retains the function of CD3 and DLL3.

Anti-CD3 & DLL3 Reference Antibody (Tarlatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-CD3 & DLL3 Reference Antibody (Tarlatamab) is 94.53%, determined by SEC-HPLC.

Tarlatamab bound to DLL3 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Tarlatamab bound to huPD-1-his, and the EC50 was 0.010 nM

Tarlatamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Tarlatamab bound to huCD3e-jurkat cells, and the EC50 was 6.141 nM.

Tarlatamab bound to hu-DLL3-HEK293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Tarlatamab bound to hu-DLL3-HEK293 cells, and the EC50 was 0.337 nM.

Co-incubation of Tarlatamab with Jurkat cells, then with the addition of hu-DLL3-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.As shown in fig, Tarlatamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.056 nM.